

Sivextro approved for adult skin infections

23 June 2014



(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.

The drug, which may be taken intravenously or orally as a pill, is designed to treat infections including methicillin-resistant *Staphylococcus aureus* (MRSA), the FDA said in a news release.

The drug's safety and effectiveness were evaluated in clinical studies involving more than 1,300 adults with serious-to-severe [skin infections](#). The most common side effects recorded were nausea, headache, diarrhea, vomiting and dizziness. The drug was not evaluated among adults with neutropenia, the agency said.

Sivextro is the second new antibiotic for skin infections to be FDA-approved in the past month, following the May 23 approval of Dalvance (dalbavancin).

Sivextro is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.

More information: [More Information](#)

[Health News](#) Copyright © 2014 [HealthDay](#). All rights reserved.

APA citation: Sivextro approved for adult skin infections (2014, June 23) retrieved 3 May 2021 from <https://medicalxpress.com/news/2014-06-sivextro-adult-skin-infections.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.